Rhodes Melissa
Chief Operating Officer
Rhodes Melissa has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Nov 19, 2026.
On the most recent filing, Rhodes Melissa is listed as Chief Operating Officer at Avalyn Pharma Inc. Inside the rolling window, Rhodes Melissa reported no open-market purchases and 1 open-market sale totaling $371K in AVLN.
Companies traded
Other insiders at AVLN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$371K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Rhodes Melissa made?
Rhodes Melissa has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company since 2026.
Which companies does Rhodes Melissa trade?
Rhodes Melissa has filed SEC Form 4 disclosures for 1 company, including AVLN.
When was Rhodes Melissa's most recent SEC Form 4 filing?
Rhodes Melissa's most recent SEC Form 4 filing on Tracefour is dated Nov 19, 2026.
What is Rhodes Melissa's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Rhodes Melissa is listed as Chief Operating Officer.
What is Rhodes Melissa's total buy and sell value in the current window?
Inside the rolling retention window, Rhodes Melissa bought $0 and sold $371K based on SEC Form 4 filings.
What was Rhodes Melissa's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 13,300 AVLN shares on 2026-11-17, worth $371K, per SEC Form 4 filings.